Identification and characterization of a neutralizing monoclonal antibody that provides complete protection against Yersinia pestis
Open Access
- 9 May 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (5) , e0177012
Abstract
Yersinia pestis (Y. pestis) has caused an alarming number of deaths throughout recorded human history, and novel prophylactics and therapeutics are necessary given its potential as a bioweapon. Only one monoclonal antibody has been identified to date that provides complete protection against Y. pestis. Here, we describe a second novel murine monoclonal antibody (F2H5) that provided complete protection against Y. pestis 141 infection when administered prophylactically to Balb/c mice (100 μg intravenously). We humanized F2H5, characterized its ability to bind to the Y. pestis F1 protein and further characterized the neutralizing epitope using computational and experimental approaches. While Western blot results suggested a linear epitope, peptide mapping using ELISA failed to identify an epitope, suggesting a conformational epitope instead. We adopted a computational approach based on Residue Contact Frequency to predict the site of antigen-antibody interaction and defined the F2H5/F1 binding site computationally. Based on computational approach, we determined that residues G104E105N106 in F1 were critical to F2H5 binding and that CDRH2 and CDRH3 of F2H5 interacted with F1. Our results show that combining computational approach and experimental approach can effectively identify epitopes.Keywords
Funding Information
- The National Natural Science Foundation of China (81172980)
- the State Project for Essential Drug Research and Development (2013ZX09304103)
This publication has 28 references indexed in Scilit:
- Acquisition of Maternal Antibodies both from the Placenta and by Lactation Protects Mouse Offspring from Yersinia pestis ChallengeClinical and Vaccine Immunology, 2012
- Human Anti-Plague Monoclonal Antibodies Protect Mice from Yersinia pestis in a Bubonic Plague ModelPLOS ONE, 2010
- Amino acid residues 196–225 of LcrV represent a plague protective epitopeVaccine, 2010
- RaxibacumabmAbs, 2009
- A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plagueVaccine, 2009
- Adenovirus-Mediated Delivery of an Anti-V Antigen Monoclonal Antibody Protects Mice against a Lethal Yersinia pestis ChallengeInfection and Immunity, 2009
- Resistance of Yersinia pestis to Antimicrobial AgentsAntimicrobial Agents and Chemotherapy, 2006
- A Phase 1 Study of PAmAb, a Fully Human Monoclonal Antibody against Bacillus anthracis Protective Antigen, in Healthy VolunteersClinical Infectious Diseases, 2005
- HADDOCK: A Protein−Protein Docking Approach Based on Biochemical or Biophysical InformationJournal of the American Chemical Society, 2003
- A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine modelVaccine, 1995